[New aspects of the determination of blood methotrexate levels in leukemic children].
Serum and CSF concentrations after medium dosage of methotrexate (MTX; 500 mg/m2 - 1,000 mg/m2) have been determined by an enzymatic assay during 142 infusions in children with ALL. If the dose of MTX was 500 mg/m2 MTX concentrations in CSF were under 10(-6) M/l in 40% of the treatments but only in 22%, when the dose was increased to 1,000 mg/m2. The systemic clearance of MTX was found to be increased significantly by the 2nd MTX treatment in children who relapsed thereafter. Such a phenomenon was not observed in children who continued in remission. The relapse free survival of children, whose MTX-clearance remained constant by the 2nd MTX treatment was significantly longer. No serious MTX toxicity has been observed in our patients.
Schuler
D
D
Borsi
J
J
Koós
R
R
Révész
T
T
Kardos
G
G
Somló
P
P
D001812:Blood-Brain Barrier; D002648:Child; D006801:Humans; D007262:Infusions, Intravenous; D007945:Leukemia, Lymphoid / Q000097:blood / Q000188:drug therapy*; D008657:Metabolic Clearance Rate; D008727:Methotrexate / Q000097:blood* / Q000627:therapeutic use; D011379:Prognosis
D008727:Methotrexate
Neue Aspekte der Methotrexat-Blutspiegelbestimmungen bei leukämischen Kindern.